Velfarm LLC launched a plant, worth more than 1.6 billion rubles, to manufacture finished dosage forms in the Kurgan region. The enterprise received the permits and will begin to manufacture two medicinal products.
For the first time in the history of the enterprise, Velfarm LLC began to produce the finished dosage forms, including Bupivacaine and Pipemidic acid.
Currently, the company completed the installation and pre-commissioning of equipment for two lines to manufacture the ampoules, two lines to manufacture the tablets and capsules, and launched the equipment for cleaning and preparation of air and water.
It is completing the stages for testing and registration of medicinal products to treat the respiratory diseases, diseases of nervous, musculoskeletal, cardiovascular systems, diseases affecting the blood formation and blood, digestive tract and metabolism.
Velfarm plans to manufacture up to 150 million ampoules of injection solutions, up to 80 million packages of coated and non-coated tablets, and 20 million packages of solid capsules a year. The total portfolio of products scheduled for manufacturing includes more than 190 medicines (with more than 40 aimed at import substitution).
24% of finished dosage forms in the planned product range are currently supplied to the Russian market only by foreign manufacturers and, so far, are not manufactured in the Russian Federation.